BioLineRx Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated January 7, 2025, reports on a registered direct offering entered into by BioLineRx Ltd. on January 6, 2025. The Company is a foreign private issuer based in Modi'in, Israel, focused on research and development of drug candidates.
Key Financial Metrics and Transaction Details
- Offering Size: 50,000,000 American Depositary Shares (ADSs) or Pre-Funded Warrants.
- Warrant Structure: Each ADS or Pre-Funded Warrant is sold with one Ordinary Warrant to purchase up to 50,000,000 ADSs.
- Pricing: $0.20 per ADS and accompanying Ordinary Warrant; $0.1999 per Pre-Funded Warrant and accompanying Ordinary Warrant.
- Gross Proceeds: Approximately $10 million (excluding future warrant exercises).
- Use of Proceeds: Research and development, pipeline expansion, working capital, and general corporate purposes.
- Transaction Costs: Placement agent fees include 7% of gross proceeds, a 1% management fee on ADS sales, $25,000 non-accountable expense allowance, $40,000 accountable expenses, and $15,950 in clearing fees.
Material Changes and Transaction Terms
The filing details a significant capital raise event rather than operational financial results. Key terms include:
- Pre-Funded Warrants: Immediately exercisable at $0.0001 per ADS; no expiration until fully exercised.
- Ordinary Warrants: Exercise price of $0.20 per ADS; 5-year term; immediately exercisable.
- Ownership Limitations: Beneficial ownership is capped at 4.99% (or 9.99% at holder election) post-exercise.
- Lock-Up Provisions: The Company is restricted from issuing new equity or filing new registration statements for 60 days post-closing. Variable rate transactions are restricted for one year.
- Placement Agent Warrants: H.C. Wainwright & Co., LLC receives warrants for 2,500,000 ADSs (5% of the offering) at an exercise price of $0.25, expiring January 6, 2030.
Outlook, Risks, and Contingencies
The Offering is expected to close on or about January 7, 2025, subject to customary closing conditions. The filing includes standard forward-looking statement disclaimers, noting that the closing is not guaranteed and depends on the satisfaction of conditions. The Company undertakes no obligation to update these statements.
Investor Verification Checklist
- Confirm the actual closing date and final gross proceeds received.
- Verify the final mix of ADSs versus Pre-Funded Warrants sold to investors.
- Review the updated capitalization table to assess dilution from the 50,000,000 new ADSs and associated warrants.
- Monitor the Company's cash runway extension relative to the $10 million gross proceeds and transaction fees.
- Check for any subsequent filings regarding the 60-day lock-up period expiration.